The U.S. Food and Drug Administration (FDA) is set to hold a significant virtual symposium in 2023, focusing on the continuous manufacturing of nanomaterials. Termed the 2023 NanoDay Symposium, the event will take place on October 11, 2023.
In this forthcoming symposium, the FDA is expected to provide an overview of the experiences of the Center for Drug Evaluation and Research (CDER) in approving a number of solid oral drug products that have gained benefits from continuous manufacturing technologies. This will offer an invaluable opportunity for law professionals working in corporations and firms within the pharmaceutical, healthcare, and nanotech sectors, to gain insights into how FDA approval processes operate in the context of advanced manufacturing techniques.
Continuous manufacturing embodies a production method that stands at the vanguard of modern industrial strategies, particularly in industries such as pharmaceuticals. It entails streamlining processes, whereby raw materials are consistently transformed into finished products without interruptions or downtime. The advantages of this manufacturing approach are numerous, including potential improvements in product quality, simplified scaling, and better responsiveness to market demand. Understanding the legal connotations and regulatory considerations of this manufacturing paradigm will be crucial for legal professionals in pertinent sectors.
It’s worth noting that the symposium will be held virtually, further opening the dialogue to legal professionals worldwide, and providing them with the convenience of remote participation.
More details can be found at JD Supra, and this announcement invites all stakeholders within the legal community who are interested in experiencing this intersection of law, medicine, technology, and regulatory compliance, to keep a keen eye on updates regarding the 2023 NanoDay Symposium.